View Older Stories View More Recent Stories

May 31, 2022 08:04AM Denali Therapeutics (DNLI), Biogen (BIIB) Initiate Phase 2b Study of LRRK2 Inhibitor in Parkinson's Disease
May 31, 2022 08:00AM Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
May 31, 2022 08:00AM Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
May 9, 2022 07:31PM EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
May 5, 2022 07:32AM Biogen (BIIB) and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
May 5, 2022 07:30AM Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
May 5, 2022 07:30AM Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
May 5, 2022 07:30AM Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
May 2, 2022 06:31AM SAGE Therapeutics (SAGE) and Biogen (BIIB) Initiate Rolling NDA Submission for Zuranolone
May 2, 2022 06:30AM Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD
Apr 4, 2022 04:07PM Biogen (BIIB) Announces New Data at AAN 2022 Highlight Real-World Evidence from MS Portfolio and Emerging Research on Disease Progression
Apr 4, 2022 04:06PM New Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research on Disease Progression
Apr 4, 2022 04:06PM New Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research on Disease Progression
Mar 30, 2022 07:30AM Biogen (BIIB) Submits Final Protocol for ADUHELM Phase 4 ENVISION Trial to FDA
Mar 30, 2022 07:30AM Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
Mar 30, 2022 07:30AM Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
Mar 28, 2022 07:30AM Biogen (BIIB) and Ionis (IONS) Report Topline Phase 1 Study Results of Drug in C9orf72
Mar 28, 2022 07:30AM Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Mar 28, 2022 07:30AM Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Mar 28, 2022 07:30AM Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Mar 21, 2022 07:35PM Biogen (BIIB) and Eisai Report Latest Findings on lecanemab
Mar 21, 2022 07:30PM LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING
Mar 16, 2022 11:55AM Biogen (BIIB) Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
Mar 16, 2022 11:54AM Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
Mar 16, 2022 11:54AM Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
Mar 16, 2022 07:30AM Biogen (BIIB) Reports Long-Term Phase 3 Data Showing ADUHELM Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
Mar 16, 2022 07:30AM Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
Mar 16, 2022 07:30AM Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
Mar 14, 2022 07:00PM Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
Mar 14, 2022 07:00PM Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
Mar 14, 2022 07:35AM Biogen (BIIB) Presents Updates Across SMA Research Program
Mar 14, 2022 07:30AM Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
Mar 14, 2022 07:30AM Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
Mar 11, 2022 04:30PM Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)
Mar 11, 2022 04:30PM Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)
Mar 3, 2022 06:30PM EISAI INITIATES SUBMISSION OF APPLICATION DATA UNDER THE PRIOR ASSESSMENT CONSULTATION SYSTEM IN JAPAN WITH THE AIM OF OBTAINING EARLY APPROVAL FOR INVESTIGATIONAL ANTI-AMYLOID BETA PROTOFIBRIL ANTIBO
Feb 16, 2022 07:00AM SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints
Feb 16, 2022 07:00AM Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of
Feb 8, 2022 08:11PM HAGENS BERMAN BIIB ALERT: Investors in Biogen Inc. (BIIB) With Significant Losses Have Opportunity to Lead Securities Class Action
Feb 7, 2022 04:05PM Biogen (BIIB) and Xbrane Enter Commercialization and License Agreement for CIMZIA
Feb 7, 2022 04:05PM Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
Feb 7, 2022 04:05PM Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
Feb 1, 2022 07:35AM Biogen (BIIB) Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
Feb 1, 2022 07:30AM Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
Feb 1, 2022 07:30AM Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
Jan 31, 2022 07:32AM Biogen (BIIB) Announces Retirements of Nancy Leaming and Brian Posner from Board
Jan 31, 2022 07:30AM Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
Jan 31, 2022 07:30AM Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
Jan 27, 2022 06:50PM Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
Jan 27, 2022 06:50PM Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
View More Recent Stories View Older Stories